## Abstract Siliconβsubstituted hydroxyapatite (SiβHA) has been shown to lead to significantly increased rates of bone apposition when compared with phaseβpure hydroxyapatite (HA) bioceramic implants (Patel N, et al. J Mater Sci Mater Med 2002;13:1199β1206). However, uncertainty remains about the m
Development of Sr and CO3 co-substituted hydroxyapatites for biomedical applications
β Scribed by Elena Landi; Simone Sprio; Monica Sandri; Giancarlo Celotti; Anna Tampieri
- Publisher
- Elsevier Science
- Year
- 2008
- Tongue
- English
- Weight
- 567 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1742-7061
No coin nor oath required. For personal study only.
β¦ Synopsis
Sr and CO 3 co-substituted hydroxyapatite (SrCHA) nanopowder was synthesized by neutralization. The powder was characterized. The improved solubility in Hanks' balanced solution of SrCHA granules (400-600 lm of dimensional range), potentially usable as bone filler, was assessed and compared with that of an analogous carbonate free granulate. SrCHA porous bodies with interconnected microand macro-porosity, which mimic the morphology of spongy bone, were prepared by the impregnation of cellulose sponges with suspensions of the SrCHA powder and controlled sintering. SrCHA porous scaffolds sintered at 850 Β°C, in flowing CO 2 atmosphere, showed satisfying compressive strength (4.58 Β± 0.75 MPa) for a porosity value of 45 vol.% and retained the desired ionic substitutions (Sr/ Ca = 0.11 and CO 3 = 6.8 wt.%). The possibility of widely modulating, by acting on the chemical-physical-geometrical features of the material, the prolonged in situ release of therapeutic Sr, together with the fundamental (Ca, PO 4 ) and main substituting (CO 3 ) ions that constitute the bone mineral phase, makes the use of SrCHA as resorbable bone filler or bone substitute scaffolds promising, especially when pathologies related with Sr deficiency are present. In vitro and in vivo tests are in progress.
π SIMILAR VOLUMES